去铁铵
中文名称 | 去铁铵 |
---|---|
中文同义词 | 甲磺酸去铁胺;甲磺酸去铁敏;甲磺酸除铁灵;去铁铵/去铁敏;DEFEROX胺甲磺酸盐;去铁铵;去铁胺甲磺酸酯;去铁胺甲磺酸盐 |
英文名称 | DEFEROXAMINE MESYLATE |
英文同义词 | deferoxaminemesilate;deferoxaminemethanesulfonate;desferalmesylate;desferalmethanesulfonate;desferrioxaminebmesylate;Deferoxamine Mesylate (300 mg);N-[5-[3-[(5-aMinopentyl)hydroxycarbaMoyl]propionaMido]pentyl]-3-[[5-(N-hydroxyacetaMido);N1-(5-aMinopentyl)-N1-hydroxy-N4-[5-[[4-[[5-(acetylhydroxyaMino)pentyl]aMino]-1,4-dioxobutyl]hydroxyaMino]pentyl]butanediaMide Methanesulfonate |
CAS号 | 138-14-7 |
分子式 | C26H52N6O11S |
分子量 | 656.79 |
EINECS号 | 205-314-3 |
相关类别 | 医药中间体;小分子抑制剂;小分子抑制剂,天然产物;医药原料药-科研原料;医药原料;Aliphatics;Amines;Chelating Agents & Ligands;Intermediates & Fine Chemicals;Pharmaceuticals;DESFERAL;Inhibitors;试剂盒-细胞分析试剂盒;标准品 |
Mol文件 | 138-14-7.mol |
结构式 |
去铁铵 性质
熔点 | 148-149° |
---|---|
储存条件 | 2-8°C |
溶解度 | H2O:50 mg/mL |
形态 | 粉末 |
颜色 | 白色至类白色 |
水溶解性 | Soluble to 100 mM in water |
Target | Value |
HIF-1α
() | |
Beta Amyloid
() | |
Ferroptosis
() |
Deferoxamine treatment significantly increases HIF-1α binding under all culture conditions, including hypoxic and high-glucose. The mechanism of deferoxamine is through improving HIF-1α biological function through scavenging oxygen free radicals. Deferoxamine (5 μM) has significant effect on the tumor-associated stromal cells cellular multiplication, and cells die at day 7 after exposure to 50 μM and 100 μM deferoxamine. Deferoxamine (5 μM-100 μM) inhibits the proliferation of BMMSCs, and induces apoptosis of MSCs in a dose-dependent manner. Deferoxamine influences the expression of adhesion proteins on MSCs. Deferoxamine (30, 60, 120 μM) shows lower expression of HIF-1α in a concentration dependent way in AdMSCs.
Deferoxamine (100 mg/kg, i.p.) lowers the mortality rate of subarachnoid hemorrhage (SAH) rat. Deferoxamine (100 mg/kg, i.p.) attenuates Evan’s blue extravasation in cortex, ameliorates the tight junction detachment and preserves the integrity of the base membrane examined in electron microscope at day 3 after SAH. Deferoxamine attenuates degradation of BBB proteins after SAH and significantly reduces ferritin expression at day 3 in the cortex, and improves neurologic behavior and cognitive deficits after experimental. Ten µL of 1 mM deferoxamine-treated wounds display significantly accelerated healing from day 7 onward and heal significantly faster than control-treated wounds in diabetic mice. Deferoxamine-treated wounds and dimethyloxalylglycine-treated wounds heal significantly faster than control-treated wounds in aged mice. In deferoxamine (10 mg/mL)-treated TG mice, there is a decrease in both soluble and insoluble Aβ40 and Aβ42. Both pGSK3β and β-catenin are significantly increased by approximately 50% in the deferoxamine-treated mice.
安全信息
安全说明 | 22-24/25 |
---|---|
WGK Germany | 2 |
RTECS号 | UG5310000 |
海关编码 | 29280000 |
毒性 | man,TDLo,parenteral,16gm/kg/34W-I (16000mg/kg),CARDIAC: PERICARDITISGASTROINTESTINAL: ULCERATION OR BLEEDING FROM SMALL INTESTINEBLOOD: OTHER CHANGES,American Journal of Kidney Diseases. Vol. 10, Pg. 71, 1987. |
提供商 | 语言 |
---|---|
英文
|